» Articles » PMID: 35708320

Aberrant Neuregulin 1/ErbB Signaling in Charcot-Marie-Tooth Type 4D Disease

Overview
Journal Mol Cell Biol
Specialty Cell Biology
Date 2022 Jun 16
PMID 35708320
Authors
Affiliations
Soon will be listed here.
Abstract

Charcot-Marie-Tooth type 4D (CMT4D) is an autosomal recessive demyelinating form of CMT characterized by progressive motor and sensory neuropathy. N-myc downstream regulated gene 1 () is the causative gene for CMT4D. Although more CMT4D cases have been reported, the comprehensive molecular mechanism underlying CMT4D remains elusive. Here, we generated a novel knockout mouse model in which the fourth and fifth exons of the gene were removed. -deficient mice develop early progressive demyelinating neuropathy and limb muscle weakness. The expression pattern of myelination-related transcriptional factors, including SOX10, OCT6, and EGR2, was abnormal in -deficient mice. We further investigated the activation of the ErbB2/3 receptor tyrosine kinases in -deficient sciatic nerves, as these proteins play essential roles in Schwann cell myelination. In the absence of NDRG1, although the total ErbB2/3 receptors expressed by Schwann cells were significantly increased, levels of the phosphorylated forms of ErbB2/3 and their downstream signaling cascades were decreased. This change was not associated with the level of the neuregulin 1 ligand, which was increased in -deficient mice. In addition, the integrin β4 receptor, which interacts with ErbB2/3 and positively regulates neuregulin 1/ErbB signaling, was significantly reduced in the -deficient nerve. In conclusion, our data suggest that the demyelinating phenotype of CMT4D disease is at least in part a consequence of molecular defects in neuregulin 1/ErbB signaling.

Citing Articles

PMP2 regulates myelin thickening and ATP production during remyelination.

Hong J, Garfolo R, Kabre S, Humml C, Velanac V, Roue C Glia. 2024; 72(5):885-898.

PMID: 38311982 PMC: 11027087. DOI: 10.1002/glia.24508.


Imbalance of NRG1-ERBB2/3 signalling underlies altered myelination in Charcot-Marie-Tooth disease 4H.

El-Bazzal L, Ghata A, Esteve C, Gadacha J, Quintana P, Castro C Brain. 2022; 146(5):1844-1858.

PMID: 36314052 PMC: 10151191. DOI: 10.1093/brain/awac402.

References
1.
Li L, Liu G, Liu Z, Lu C, Wu Z . Identification and functional characterization of two missense mutations in NDRG1 associated with Charcot-Marie-Tooth disease type 4D. Hum Mutat. 2017; 38(11):1569-1578. DOI: 10.1002/humu.23309. View

2.
Okamoto Y, Goksungur M, Pehlivan D, Beck C, Gonzaga-Jauregui C, Muzny D . Exonic duplication CNV of NDRG1 associated with autosomal-recessive HMSN-Lom/CMT4D. Genet Med. 2013; 16(5):386-394. PMC: 4224029. DOI: 10.1038/gim.2013.155. View

3.
He W, Bai G, Zhou H, Wei N, White N, Lauer J . CMT2D neuropathy is linked to the neomorphic binding activity of glycyl-tRNA synthetase. Nature. 2015; 526(7575):710-4. PMC: 4754353. DOI: 10.1038/nature15510. View

4.
Heller B, Ghidinelli M, Voelkl J, Einheber S, Smith R, Grund E . Functionally distinct PI 3-kinase pathways regulate myelination in the peripheral nervous system. J Cell Biol. 2014; 204(7):1219-36. PMC: 3971744. DOI: 10.1083/jcb.201307057. View

5.
Gouttenoire E, Lupo V, Calpena E, Bartesaghi L, Schupfer F, Medard J . Sh3tc2 deficiency affects neuregulin-1/ErbB signaling. Glia. 2013; 61(7):1041-51. DOI: 10.1002/glia.22493. View